New patent office polices may make it harder for lower-cost medicines to reach consumers

Taking stock of the drug industry, from the lab to the medicine chest

November 13, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Joe Raedle/Getty Images STAT+ | New patent office polices may make it harder for lower-cost medicines to reach consumers At issue is an agency procedure called inter partes reviews, or IPRs, that have been used to address patent disputes. By Ed Silverman STAT+ | Uniqure's CEO dined with investors. Here's what he said The company is hoping to find a way forward with an FDA submission of its gene therapy for Huntington's disease. By Adam Feuerstein Opinion: This era of weight loss drugs requires a new kind of health platform People using GLP-1s for weight loss need tech support—but not in the form of metrics-obsessed wellness apps By David A. Shaywitz Children's Hospital of Philadelphia STAT+ | FDA chiefs offer roadmap to expand custom gene-editing treatments like Baby KJ's Marty Makary, Vinay Prasad offer roadmap for expanding access to custom gene-editing treatments like the one used to treat Baby KJ's ultra-rare disease. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser